Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The surgical robot industry is entering a commercialization and policy acceleration phase, with significant growth potential driven by new policies and market demand [5][6][25] - The overall performance of the pharmaceutical and biotechnology sector has improved, with a notable increase in stock prices and market activity [7][29] - The innovation drug sector is experiencing a recovery, supported by advancements in technology and upcoming industry events [31][32] Summary by Relevant Sections Surgical Robot Industry - In the first eleven months of 2025, surgical robot sales reached 332 units, a slight increase of 3.75% year-on-year, with total sales amounting to 2.973 billion yuan, a minor decline of 0.87% [16] - The laparoscopic surgical robot segment accounted for 35.8% of total sales volume and 61.3% of sales revenue, while orthopedic surgical robots saw a 17.81% increase in sales volume and a 21.62% increase in sales revenue [16][17] - The national pricing framework for robotic surgeries is expected to enhance the clinical value and drive market growth [22][24] Beneficiary Companies - MicroPort MedBot has a strong global strategy and is expected to achieve breakeven in 2026, benefiting from favorable domestic policies and increasing market penetration [6][25][27] - Tianzhihang holds over 40% market share in the domestic orthopedic surgical robot market and is positioned as a leader with significant growth potential in service and consumable revenues [6][25][27] Market Performance - The A-share pharmaceutical and biotechnology sector rose by 7.81% from January 5 to January 9, 2026, outperforming the CSI 300 index by 5.03 percentage points [7][29] - The hospital sector within the pharmaceutical sub-industry saw the highest increase, with a rise of 13.92% [7][29] Innovation Drugs and Industry Chain - The innovation drug sector is expected to see continued growth, driven by new technologies and upcoming clinical data updates at the JPM conference [31][32] - The demand for R&D outsourcing is stabilizing, and the supply side is expected to recover as pricing levels reach a bottom [32] Medical Devices - The medical device sector is anticipated to gradually recover profitability, aided by policy adjustments and market corrections [34][35] - Key players in the high-value consumables market are expected to benefit from reduced competition and improved pricing strategies [35] Pharmaceutical Commerce - The number of drugstores in China has been declining, with a significant reduction in the number of stores, indicating a consolidation phase in the industry [40] - Leading drugstore chains are expected to improve profit margins in 2026 through operational optimizations and strategic adjustments [40]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

Market Performance - The Hong Kong stock market experienced volatility, with the Hang Seng Index closing down 0.41% or 106 points, ending at 26,231 points, and total trading volume reaching approximately 1.36 trillion HKD [1][5] Sector and Stock Movements - The technology sector saw most stocks decline, with the Hang Seng Tech Index dropping 0.86% to 5,687.14 points. Notable declines included Tencent down 1.93% to 611.0 HKD, Alibaba down 1.68% to 146.50 HKD, and Meituan down 5.83% to 98.50 HKD. However, Bilibili rose 11.87% to 223.40 HKD, and Trip.com increased by 2.32% to 596.50 HKD [3][4] - Gold prices surpassed 4,500 USD/ounce, attracting interest as a safe-haven asset, which positively impacted gold stocks such as Zijin Mining up 3.57% and Shandong Gold up 11.27% [3][4] Innovation and IPO Market - Reports indicate that China will enhance support for innovative drugs, leading to a rise in the biotech sector. Notable stock increases included Rongchang Biopharma up 28.51% and Jinfang Biopharma up 44.85% [4] - The IPO market in Hong Kong was active, with six new stocks listed, all recording gains on their debut. MiniMax saw a remarkable first-day increase of 109%, reaching a market value exceeding 100 billion HKD [4][7] Economic Indicators - China's December CPI data was released at 0.8%, the highest in nearly two years, while PPI showed a narrower decline, indicating positive price changes in some sectors [5] - The recent IPO activity and adjustments in Hong Kong Stock Connect are expected to attract additional southbound capital, creating a favorable trading environment [5][7]

Core Insights - The report continues to recommend innovative drugs and the related industry chain, highlighting the strong growth potential in the pharmaceutical sector through 2026 [1][4]. Investment Strategy - The investment strategy emphasizes the focus on the CXO sector, particularly in chemical CDMO, where Chinese companies hold significant advantages in talent, chemical capabilities, compliance production, and intellectual property protection [4]. - The report suggests that the upcoming JPM conference will provide updates on the operational progress of Chinese innovative drug companies, which have shown a long-term positive development trend [4]. - The recommended investment portfolio includes A-shares such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, as well as H-shares like Kangfang Biologics and WuXi Biologics [4][5]. Industry Performance - The pharmaceutical industry experienced a decline of 4.10% in December, underperforming the CSI 300 index by 6.38% [8]. - The report notes that the chemical pharmaceutical sector saw the largest declines among sub-sectors, with a drop of 5.80% [12]. Market Data - For the period from January to November 2025, the pharmaceutical manufacturing industry's total revenue was 220.65 billion yuan, reflecting a year-on-year decrease of 2.0% [7]. - The total retail sales of consumer goods reached 45.61 trillion yuan, with retail sales of Western and Chinese medicines amounting to 660.4 billion yuan, a year-on-year increase of 1.8% [7]. Regulatory Environment - The report discusses the impact of the U.S. "Biological Safety Act," which is expected to have a limited short-term effect on Chinese CXO companies, while emphasizing the need to monitor the long-term implications of international competition and regulatory changes [22]. Recent Drug Approvals - In December 2025, a total of 16 innovative drugs or biosimilars were approved for market entry, including six domestic and ten imported products [24][25].

行 业 研 医药生物 2026 年 01 月 11 日 医药生物 究 医药科技开门红，小核酸 FXIa 即将催化（建议 关注瑞博、靖因） 投资要点： 行 业 定 期 报 告 行情回顾：本周（2026 年 1 月 5 日- 2026 年 1 月 9 日）中信医药指数上涨 7.7%，跑赢沪深 300 指数 4.9 pct，在中信一级行业分类中排名第 5 位；2026 年初至今中信医药生物板块指数上涨 7.7%，跑赢沪深 300 指数 4.9 pct，在中 信行业分类中排名第 5 位。本周涨幅前五的个股为：创新医疗（+61.0%）、三 博脑科（+56.2%）、美好医疗（+56.1%）、前沿生物（+56.0%）、悦康药业 （+40.6%）。 FXIa 抑制剂即将迎来催化，小核酸方向建议关注瑞博、靖因：血栓性 疾病全球每年发病人群高达 2670 万，目前针对血栓性疾病的抗凝药物主要 包括华法林、肝素和直接口服剂，全球抗凝血药物市场预计在 2024 年高达 330 亿美金。但是现有抗凝血药物的作用是非选择性的，既影响凝血的内 源性途径，也影响外源性途径以及共同下游途径，这种治疗方法不可避免 地会损害正常应对损伤的止血反应 ...

Core Viewpoint - The Chinese innovative drug industry is entering a new phase of "earning dollars," prompting public funds to rapidly launch new pharmaceutical funds in early 2026 [1][3]. Group 1: Fund Launches and Market Activity - In the first week of 2026, there has been a surge in new fund launches focused on innovative drugs, with significant investments directed towards the Hong Kong pharmaceutical sector [3][4]. - Notable new products include the Hua Bao Hong Kong Medical Theme ETF, which raised 331 million yuan and quickly built a stock position of 14.70% [3]. - The Fu Guo Hang Seng Biotechnology ETF also launched, raising over 320 million yuan and focusing on leading Hong Kong pharmaceutical companies [3][4]. Group 2: Performance and Demand for Pharmaceutical Funds - The strong performance of Hong Kong pharmaceutical funds in 2025 has heightened demand from both institutional and retail investors for new pharmaceutical fund offerings [6][7]. - The Hong Kong pharmaceutical theme funds delivered impressive returns in 2025, with some achieving over 113% cumulative returns, significantly influencing investor interest [6][7]. - Despite a market correction at the end of 2025, this has created an opportunity for new funds to lock in low-priced assets, leading to a rebound in fund net values [6]. Group 3: Future Expectations and Market Trends - The innovative drug sector is expected to experience a "performance verification phase" in 2026, with key indicators such as revenue from business development (BD) payments and the sales growth of core innovative drugs being closely monitored [9]. - Fund managers anticipate that 2026 will see more products entering large-scale global Phase III clinical trials, which could enhance market confidence and drive up the global value of innovative drugs [8][9]. - The industry is viewed as transitioning from following innovation to achieving global commercialization, with expectations that more Chinese innovative drug companies will realize overseas commercialization by 2027, leading to a systematic revaluation of the sector [9].

Core Viewpoint - The Chinese innovative pharmaceutical industry is entering a "dollar-earning" phase, prompting public funds to rapidly launch new medical funds in early 2026 [2][3]. Group 1: Fund Launches and Market Trends - In the first week of 2026, there has been a surge in new fund launches focused on innovative pharmaceuticals, driven by the industry's transition to global commercialization [2][3]. - Public funds are increasingly targeting the Hong Kong pharmaceutical sector, with new products like the Huabao Hong Kong Medical Theme ETF and the Fuguo Hang Seng Biotechnology ETF being launched to capitalize on this trend [3][4]. - The demand for innovative pharmaceutical funds is being fueled by the strong performance of Hong Kong pharmaceutical funds in 2025, which saw significant returns, such as the Huatai-PineBridge Hong Kong Advantage Select QDII fund achieving a cumulative return of 113% [5][6]. Group 2: Investment Strategies and Expectations - Fund managers believe that the global commercialization of innovative drugs is a key characteristic for the emergence of industry giants, and this transition is expected to lead to a new valuation phase for the sector [2][7]. - The innovative pharmaceutical sector is anticipated to experience a "performance verification phase" in 2026, with key indicators such as the realization of upfront payments and the sales growth of core innovative drugs being closely monitored [8]. - The market is expected to see a systematic valuation reshaping starting in 2027, as more Chinese innovative pharmaceutical companies achieve overseas commercialization [8].

Core Viewpoint - The article discusses the initiation of a Phase III clinical trial for HB0025, a drug developed by Huahai Pharmaceutical's subsidiary, Huatai, aimed at treating advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy [1][4]. Group 1: Clinical Trial Details - The clinical trial, registered under CTR20260016, is a randomized, double-blind, multi-center study named DUALIGHT-02, which will evaluate the efficacy and safety of HB0025 in comparison to pembrolizumab combined with chemotherapy [2][4]. - The trial aims to enroll 480 participants in China, with the primary endpoint being progression-free survival (PFS) assessed by blinded independent central review (BICR) according to RECIST v1.1 criteria [4]. - The drug HB0025 is an innovative PD-L1/VEGF dual-specific fusion protein designed to target both tumor immune evasion pathways and tumor angiogenesis pathways, providing a dual mechanism of action [4]. Group 2: Drug Development Status - HB0025 has reached Phase III clinical trials in China, while it is currently in Phase II globally for various cancers, including hepatocellular carcinoma and triple-negative breast cancer [5][9]. - The drug has shown promising results in earlier trials, with an objective response rate (ORR) of 83.3% in the squamous NSCLC cohort and 100% in the high PD-L1 expressing group, along with a disease control rate (DCR) of 95.8% [7]. - Huahai Pharmaceutical has invested approximately 326 million yuan in the development of HB0025 [9].

Core Insights - The biopharmaceutical industry is at a pivotal moment as it transitions from the "14th Five-Year Plan" to the "15th Five-Year Plan," emphasizing the balance between technological innovation and value-driven growth [1] - The recent surge in the innovative drug sector, with the Shanghai Composite Index achieving a 14-day winning streak and the Hong Kong innovative drug index rising by an average of 12% over three days, indicates strong market support for innovative pharmaceuticals [4] - The Chinese government has reinforced its commitment to the innovative drug sector through policies like "Full Chain Support for Innovative Drug Development," which is expected to create significant industry opportunities [4] Industry Growth Drivers - Innovative drugs are recognized as a critical new productive force, comparable in priority to AI and other emerging technologies, with substantial government backing [4] - In 2025, China signed over 150 new business development (BD) agreements in the innovative drug sector, totaling more than $130 billion, a 150% increase from 2024, with upfront payments reaching $7 billion [5] - The anticipated "milestone" rewards from these agreements could exceed $30 billion in the next 3-5 years, fostering the growth of China's innovative drug market despite inherent development risks [5] Market Dynamics - The global biopharmaceutical development landscape is revitalizing due to expiring drug patents and a favorable interest rate environment, with major pharmaceutical companies increasing their R&D investments [6] - The emergence of blockbuster innovative drugs in China, such as AK112 and SKB264, showcases the potential for significant sales in the global market, with some products challenging established leaders [6][7] - The international geopolitical climate is expected to enhance China's economic prospects, leading to increased capital inflows into A-shares and Hong Kong stocks, signaling the onset of a major bull market [7] Future Outlook - The period between 2026 and 2027 is anticipated to yield significant clinical breakthroughs in innovative drugs, potentially leading to substantial stock price revaluations [7] - The next 20 years are projected to be a prosperous era for China, with substantial returns expected for those following technological innovations in the biopharmaceutical sector [8]

Group 1 - The Hong Kong Stock Exchange (HKEX) will launch six new stock options on January 19, 2026, expanding the stock options market and providing investors with more choices [2] - The new stock options will include Zijin Mining International (02259), WuXi AppTec (02359), BeiGene (06160), Lao Poo Gold (06181), Horizon Robotics (09660), and CanSino Biologics (09926) [2] - The average daily trading volume of the derivatives market at HKEX reached a record high of 1,662,751 contracts last year, representing a 7% year-on-year increase [2] Group 2 - Stock options, including monthly and weekly expiry contracts, were among the most actively traded products, with an average daily trading volume of 879,831 contracts, marking a 22% year-on-year increase [2] - The new stock options will have varying contract sizes, such as 200 shares for Zijin Mining International and BeiGene, and 500 shares for WuXi AppTec [3] - The launch will include contracts for multiple months in 2026, specifically January, February, March, April, June, September, and December for certain stocks [3]